NCT02615795.

Methods	Study design: unknown centres; open‐label, parallel individual randomised controlled trial in Denmark Duration: 26 weeks Setting: hospital
Participants	Population: 160 adults recruited from Denmark Baseline characteristics: unknown Inclusion criteria: COPD with FEV₁/FVC < 70% at all times during study, FEV₁ < 51% during inclusion and during further study, included into study during hospitalisation with exacerbation in pulmonary symptoms Exclusion criteria: alcohol or drug abuse, not able to use equipment or with language barrier, asthma, psychiatric issues causing disability, unstable heart disease, terminal disease, not able to given written or verbal consent
Interventions	Measurements taken at baseline and at 12 months Treatment arms Telemonitoring using the Tunstall monitor device to send data to medical staff for review the same day
Outcomes	Primary outcomes: hospitalisation days Secondary outcomes: mortality, contact with GP, QOL: SGRQ, HADS, SF‐36, physiological measurements detecting COPD exacerbation, number of self‐addressed COPD exacerbations, emergency room visits COPD‐related, number of hospitalisations for COPD exacerbations, length of hospital days for COPD exacerbations
Notes	Funding: University of Aarhus Other identifier:NCT02615795; UAarhusFA